The growth suppressive properties of the tumor suppressor protein p53 are activated upon DNA damage. The activation of p53 is re¯ected in increased p53 levels which are, at least in part, the result of an extended halflife of the protein. Although this suggests that stabilization of p53 is an intrinsic feature of p53 activation, the mechanisms involved in p53 degradation and stabilization are poorly understood. Here we report on the identi®ca-tion of an internal deletion mutant of wild-type p53, termed D62 ± 96, which can be stably expressed in various cell lines. This deletion mutant has a turnover rate similar to wild-type p53 and its stability is upregulated by treatment with UV light. In cell lines that express endogenous mutant or no p53, however, D62 ± 96 appears to be stable, strongly indicating that these cell lines have lost the ability to degrade p53. Further characterization of D62 ± 96 by mutational analyses de®nes sequence and structural requirements for p53 degradation and indicates that none of the known p53 phosphorylation sites is essential with respect to p53 stability regulation upon UV-irradiation.
Introduction
Under normal growth conditions, the tumor suppressor protein p53 is a short-lived protein with a reported half-life ranging from 10 ± 15 min (rodent ®broblasts) to 2 ± 4 h (human keratinocytes) (Reich et al., 1983; Hubbert et al., 1992) . The high turnover rate of p53 is re¯ected in low steady state levels of the protein which, by restricting the intracellular levels of p53, presumably contributes to the control of the negative growth regulatory properties of p53. It is well established that p53 can be activated in response to DNA damage and that, concomitant with its activation, intracellular levels of p53 increase signi®cantly (Maltzman and Czyzyk, 1984; Kastan et al., 1992; Fritsche et al., 1993) . This increase in p53 levels appears to be at least in part due to an extended half-life of the protein, although other mechanisms, including increased translation eciency of the p53 message, may signi®cantly contribute to the upregulation of p53 levels (Mosner et al., 1995; Fu and Benchimol, 1997) . Despite the notion that the ubiquitin/proteasome system (Chowdary et al., 1994; Maki et al., 1996) and, probably, Mdm2 play a major role in p53 degradation, little is known about the mechanism(s) of p53 degradation.
In general, speci®city of protein degradation is achieved by the interplay between amino acid sequences or structures of a protein, i.e. the degradation signal, that confer the protein's half-life, and other proteins that are involved in the recognition of these degradation signals. Mutation of the p53 gene is the most common genetic alteration found in a variety of human cancers (Greenblatt et al., 1994; Hainaut et al., 1997) . The most common pattern seen in cancers is a missense mutation within one allele and rearrangement or deletion of the other allele. In general, mutant p53 proteins expressed in tumor cells appear to have a long half-life (Oren et al., 1981; Reihsaus et al., 1990) . Since mutant p53 proteins often adopt a dierent conformation than wt p53 (Milner, 1994) , this may indicate that a proper conformation is important for p53 to be recognized as a proteolytic substrate. However, studies examining the half-life of mutant p53s upon ectopic expression in cells containing wt p53 suggest that the turnover rate of p53 is in¯uenced by the cellular environment and may not, or only partially, be dependent on a wt p53-like conformation (Halevy et al., 1989; Midgley and Lane, 1997) .
Recently, it was reported that in transient transfection experiments, interaction of p53 with the Mdm2 oncoprotein induces the rapid degradation of p53 via a proteasome-dependent proteolytic pathway (Haupt et al., 1997; Kubbutat et al., 1997) . Since mdm2 gene expression is induced by p53 upon activation by appropriate stress signals (Momand and Zambetti, 1997; Piette et al., 1997) , this suggests that Mdm2 is a major player in p53 degradation during recovery from stress. Furthermore, it has been shown that binding of a peptide to the p53 binding pocket of Mdm2 results in accumulation of p53 (Bottger et al., 1997) indicating that Mdm2-induced degradation constitutes a major pathway for p53 degradation also under normal growth conditions. Another potential candidate involved in p53 degradation is the ubiquitinprotein ligase E6-AP. E6-AP was originally isolated as a protein that binds to the E6 oncoprotein of human papillomaviruses (HPVs) and facilitates E6-induced degradation of p53 (Huibregtse et al., 1991 Schener et al., 1993) . An intriguing possibility is that E6-AP is also involved in p53 degradation in the absence of the E6 oncoprotein. Although there is some evidence that p53 is ubiquitinated in non-HPV containing cells (Maki et al., 1996) , at present there is no experimental evidence to indicate that E6-AP is involved.
Similar to the basic mechanism of p53 degradation, little is known about how p53 stability is regulated upon treatment of cells with DNA damaging agents. Over the last few years it has become clear that phosphorylation plays an important regulatory role in the degradation of a number of proteins (for example see, Nishizawa et al., 1992; Chen et al., 1995; Lanker et al., 1996; Skowyra et al., 1997) . p53 is a well known phosphoprotein which contains a number of phosphorylation sites in the N-terminal as well as in the Cterminal region (Steegenga et al., 1996; Meek et al., 1997) , and it has been reported that mutation of the known phosphorylation sites at positions 15 and 315 aects the p53 turnover rate (Fiscella et al., 1993; Lin and Desiderio, 1993) . Again, however, if the phosphorylation status of these sites is involved in p53 stability regulation in response to DNA damage is presently unknown.
The lack of knowledge with respect to the mechanisms of p53 degradation and stability regulation is at least in part due to the lack of a cell culture system in which wt p53 can be stably expressed. Here we report that a deletion mutant of wt p53 (D62 ± 96) can be stably overexpressed in a variety of cell lines and its stability is regulated similarly to wt p53. Characterization of this mutant reveals that degradation of p53 is cell type dependent. Furthermore, mapping analysis using this deletion mutant de®nes sequence and structural requirements for p53 degradation and stability regulation.
Results

p53 is a substrate for E6-AP-mediated ubiquitination in vitro
The HPV E6 oncoprotein has been shown to utilize the cellular ubiquitin-protein ligase E6-AP to target p53 for degradation in vitro . This property of E6 is believed to contribute to the oncogenic properties of E6 by facilitating p53 degradation under conditions when p53 would normally be activated. Indeed, it has been reported that upon DNA damage, levels of p53 do not increase in cells which ectopically express E6 (Kessis et al., 1993; Foster et al., 1994) . To further understand the mechanism by which E6 can circumvent the normal stability regulation of p53, a series of deletion mutants was generated to identify regions of p53 which are required for p53 degradation in the presence and absence of E6. The ability of the various p53 mutants to serve as a substrate for E6-dependent degradation was ®rst assessed in standard in vitro ubiquitination assays. The results are summarized in Table 1 . During the course of these studies, it was observed that under certain conditions, i.e. relatively high levels of E6-AP and low salt concentration, p53 is recognized as a substrate for ubiquitination by E6-AP even in the absence of the E6 oncoprotein ( Figure 1a ). The eciency of p53 ubiquitination in the absence of E6 was rather low as only a limited number of p53 molecules was ubiquitinated and only a few ubiquitin molecules (3 ± 6) were attached to p53 (compare Figure  1a and b). However, this process appeared to be speci®c in that certain deletion mutants, such as DN43 E6-AP, ubiquitination of p53 induced by E6-AP in the absence of the HPV-16 E6 oncoprotein; E6, ubiquitination of p53 induced by the E6-AP/E6 complex. The various forms of p53 used are described in Materials and methods. +, serves as a substrate for ubiquitination with a similar eciency to wt p53; +/ ±, serves as a ubiquitination substrate but with a signi®cantly reduced eciency compared with wt p53; ±, ubiquitination was not observed Figure 1 E6-AP-facilitated ubiquitination of p53 in vitro. The indicated forms of p53 were generated in rabbit reticulocyte lysate in the presence of 35 S-labeled methionine. (a) and (c) The indicated radiolabeled p53 forms were incubated with E1, UbcH7, ubiquitin, and increasing amounts (0.1 mg, 0.3 mg, and 0.5 mg indicated as 1, 3, 5, respectively) of baculovirus-expressed E6-AP as indicated. After 2 h at 258C, reaction mixtures were subjected to SDS-polyacrylamide gel electrophoresis followed bȳ uorography. (b) Radiolabeled wt p53 was incubated with increasing amounts of rabbit reticulocyte lysate translated HPV E6 oncoprotein (1 ml, 3 ml, and 5 ml, indicated as 1, 3, 5, respectively) under conditions described previously (Schener et al., 1992) . After 2 h at 258C, radiolabeled p53 was detected as detailed above. Note that HPV E6-induced ubiquitination of p53 was assayed in the absence of additional recombinant E6-AP, E1, and UbcH7 (note that rabbit reticulocyte lysate already contains endogenous E6-AP). The running position of unmodi®ed p53 forms is indicated by an arrowhead, the running position of ubiquitinated p53 forms is marked with an asterisk. 7, p53 was incubated in the absence of recombinant E6-AP or the HPV-16 E6 oncoprotein (Figure 1c) which lacks the N-terminal 43 amino acids, were not recognized by E6-AP as ubiquitination substrates. Furthermore, the sequence and structural requirements of p53 to serve as a substrate for ubiquitination were dierent in the absence and in the presence of E6 (Table 1) . While oligomerization of p53 was apparently not required for E6-facilitated ubiquitination (KEEK; Table 1), it was required in the absence of E6. Similarly, a region comprising amino acid residues 20 ± 43 of p53 seemed to be essential for ubiquitination mediated by E6-AP alone but not in the presence of E6.
To test whether the dierences observed in vitro re¯ect dierent sequence requirements for p53 degradation in the absence and the presence of E6 within a cell, the turnover rate of the various deletion forms of wt p53 was determined in transient transfection experiments. While the results obtained for E6-mediated degradation correlated with the ubiquitination results obtained in vitro, neither wt p53 nor any of the deletion mutants tested were subjected to degradation to a signi®cant extent in the absence of co-transfected E6 (data not shown).
Degradation of N-terminal deletion mutants of p53 in RKO cells
To determine the sequence requirements for p53 degradation in the absence of E6, establishment of cell lines that stably express deletion forms of wt p53 was attempted. Initially, ®ve constructs were used (DN20, DN43, D44 ± 61, D62 ± 96, DC30) and for three of these (DN43, D44 ± 61, D62 ± 96) cell lines could be established that ectopically express the respective protein. As parental cells for these studies, the wt p53 expressing cell line RKO (derived from colon carcinoma) was used since this cell line is known to be pro®cient with respect to p53 degradation and stability regulation (Kessis et al., 1993) .
In the ®rst instance, to test whether the deletion mutants of p53 were subjected to degradation and stability regulation, the steady state levels of the respective proteins were determined under normal growth conditions and upon treatment of the cells with UV light. As shown in Figure 2a , the levels of DN43 increased to an extent similar to the endogenous wt p53 upon UV treatment (approximately ®vefold). This suggested that DN43 is a short-lived protein and that its stability is upregulated upon DNA damage. To test this hypothesis directly, the half-life of DN43 was determined in the presence of the protein synthesis inhibitor cycloheximide (Figure 2b ) or by pulse-chase experiments using 35 S-methionine (data not shown). This revealed, however, that the half-life of DN43 is signi®cantly extended (more than 8 h) in contrast to wt p53 (approximately 1 ± 2 h) under normal growth conditions. This strongly indicates that the increase in steady state levels of DN43 upon UV treatment is not due to an increased half-life of the protein. Thus, determination of steady state protein levels is not a suitable assay to study p53 degradation and regulation thereof (see also Discussion). In the following, therefore, the half-life of all the p53 forms tested were determined by both cycloheximide experiments (Figures 2 ± 4, 6, 7) and by pulse-chase analyses (data not shown).
Determination of the half-life of the two other deletion mutants that were stably expressed in RKO cells (i.e. D44 ± 61 and D62 ± 96) revealed that both were degraded (Figure 2d and e) and that the half-life of both was extended upon UV treatment ( Figure 2e and data not shown). It should be noted that in pulse-chase experiments, the extent of stabilization seemed to be more predominant than in cycloheximide experiments. This may indicate that either a short-lived protein is involved in p53 stability regulation or that the presence of radioactively labeled methionine in the cell further enhances the UV-induced stabilization of p53.
The half-life of p53 is dependent on the cellular environment
Studies examining the expression of tumor derived mutant p53 proteins in wt p53 containing cells had suggested that degradation of p53 is dependent on the cellular environment (Halevy et al., 1989; Midgley and Lane, 1997) . To test this hypothesis, the D62 ± 96 form of wt p53 was stably expressed in a number of cell lines which dier in their endogenous p53 status. The cell lines used were, U2OS (osteosarcoma) and mouse 3T3 cells, both of which express wt p53; the p53-negative cell lines H1299 (nonsmall cell lung cancer), H358 (nonsmall cell lung cancer), and Saos-2 (osteosarcoma); and C33-A (cervical carcinoma) which expresses a mutant p53 (point mutation at codon 273). In U2OS ( Figure 3a ) and 3T3 cells (data not shown) the D62 ± 96 deletion mutant was degraded at a rate similar to the endogenous wt p53 under normal growth conditions. 2 ) or not, as indicated. 16 h after UV treatment, whole cell extracts were prepared and p53 levels determined by immunoblotting using the p53 speci®c monoclonal antibody PAb 1801 (see Materials and methods). (b-e) Cycloheximide (60 mg/ml) was added to RKO cells expressing the indicated deletion mutants of wt p53. Protein extracts were prepared 0 h, 2 h, 4 h, and 8 h after addition of cycloheximide as indicated and p53 levels determined by immunoblotting using the p53 speci®c monoclonal antibody DO-1. In case of UV-irradiation (indicated as UV), cycloheximide was added 5 min after UV treatment. The running positions of endogenous wt p53 (wt) and the respective deletion mutants (DN43, D44 ± 61, D62 ± 96) are indicated Furthermore, treatment of these cells with UV light resulted in a signi®cantly extended half-life of both the endogenous wt p53 and the ectopically expressed D62 ± 96 form. In contrast, in H1299, H358, Saos-2 ( Figure  3b) , and C33-A cells (data not shown) the D62 ± 96 form had a half-life of more than 8 h and the half-life did not appear to be further increased upon UVtreatment (data not shown).
Next, expression constructs were generated encoding for the D62 ± 96 form of several tumor derived mutant p53s (135Y, 154V, 179Q, 273H) and stably expressed in RKO and H1299 cells, respectively. The D62 ± 96 deletion mutant was used for these experiments since it can be easily distinguished from the endogenous wt p53 protein by virtue of its smaller size. Furthermore, this particular set of tumor-derived mutants was used because they appear to dier in their conformation as judged by their dierent abilities to interact with the HPV E6 oncoprotein. The 273H interacts with E6 with an eciency similar to wt p53 (MS, unpublished data), the 135Y and 154V mutants do not detectably interact with E6, while the 179Q mutant shows an intermediate phenotype (Schener et al., 1992) .
Similar to the situation with the D62 ± 96 form of wt p53, half-life determination revealed that each of these tumor-derived mutants were degraded in RKO cells (Figure 4 ), while they remained stable in H1299 cells (data not shown). Thus, it appears that a wt-like structure, as determined by interaction with the HPV E6 oncoprotein, is not a critical determinant for recognition of p53 as a proteolytic substrate. Moreover, as shown for the 273H mutant, the half-life of these tumor-derived mutants can be upregulated upon UV-irradiation. It should be noted that these experiments do not exclude the possibility that the exact halflife and the extent of UV-induced stabilization may vary slightly between dierent mutants.
Taken together, the data presented above clearly show a cell type dependence for p53 degradation and indicate that ecient degradation occurs only in cells that harbor endogenous wt p53 protein. Since mdm2 gene expression is regulated by p53 (for recent reviews see, Momand and Zambetti, 1997; Piette et al., 1997) and Mdm2 appears to play a major role in p53 degradation (Haupt et al., 1997; Kubbutat et al., 1997; Bottger et al., 1997) , Mdm2 protein levels were determined in the dierent cell lines used ( Figure 5 ). This revealed that Mdm2 levels were consistently lower (3 ± 5-fold) in p53-negative cell lines than in wt p53 expressing cell lines. Thus, the inability of cells lacking transcriptionally active p53 to target p53 for degradation may, at least in part, be explained by the availability of insucient amounts of Mdm2 (see Discussion).
Sequence requirements for p53 degradation
To map the minimal sequence requirements for p53 degradation, the D62 ± 96 form of wt p53 was used as a backbone for generating progressive N-terminal and Cterminal deletion mutants. The half-lives of these mutants was then determined in cell lines (RKO) stably expressing the individual mutant proteins. As shown in Figure 6a , deletion of the N-terminal 20 or 43 amino acid residues resulted in a p53 molecule with a signi®cantly extended half-life compared to wt p53, with the DN20 mutant being degraded at a slightly higher rate (approximate half-life of 8 ± 10 h) than the DN43 mutant (half-life of signi®cantly greater than 8 h). In this context it should be noted that in some, Figure 4 Degradation of tumor derived p53 mutants in RKO cells. RKO cells expressing the D62 ± 96 form of the indicated tumor derived mutant p53s (273H, 135Y, 154V, 179Q) were established and the half-life of the respective mutants determined in cycloheximide experiments under normal growth conditions or upon UV-irradiation (indicated as UV). The p53 proteins were detected by immunoblotting using the p53 monoclonal antibody DO-1. The running position of endogenous wt p53 is indicated with an asterisk and the running positions of the D62 ± 96 form of the respective mutant p53s are indicated with an arrowhead Figure 5 Mdm2 levels are decreased in p53-negative cell lines. Whole cell extracts were prepared from the dierent cell lines, as indicated, and Mdm2 detected by immunoprecipitation/Western blot analysis (see Materials and methods). As a positive control, extract prepared from the Mdm2-overexpressing cell line OSA was used Figure 3 Degradation of p53 is cell type dependent. The D62 ± 96 deletion mutant of wt p53 was stably expressed in dierent cell lines (U2OS, H1299, H358, Saos, as indicated) and the half-life determined in cycloheximide experiments as described in the legend to Figure 2 . In addition, the half-life of D62 ± 96 was determined upon UV-irradiation (indicated as UV). The running positions of endogenous wt p53 and D62 ± 96 are marked with an asterisk or an arrowhead, respectively. Note that U2OS cells express endogenous wt p53, while H1299, [H358,. . . ] H358, and Saos-2 cells contain no endogenous wt p53 but not all experiments, the half-life of the endogenous wt p53 appeared to be extended by the presence of the N-terminal truncation mutants. Since oligomerization of p53 appears to be a prerequisite for p53 degradation, as determined by examining the half-life of a oligomerization-negative form of p53 (designated as KEEK, see Table 2 ) (StuÈ rzbecher et al., 1992) , this suggests that hetero-oligomeric forms of p53 consisting of wt p53 and N-terminal truncation mutants are not eciently recognized by the proteolytic system (see Discussion).
Deletion of the C-terminal 30 amino acids resulted in a protein with a half-life similar to the endogenous wt p53 (Figure 6b ). The speci®city of DC30 degradation is shown by the observation that its half-life is greatly extended upon UV treatment. In contrast, deletion of the C-terminal 66 amino acids resulted in a stable protein further supporting the notion that oligomerization is important for p53 degradation.
Stability regulation of p53 phosphorylation mutants
The C-terminal 30 amino acids of p53 contain several known phosphorylation sites (Steegenga et al., 1996) . The observation that the DC30 deletion mutant is stabilized by DNA damage strongly indicates that the phosphorylation status of this particular region of p53 is not essential for p53 stability regulation. This was further supported by the ®nding that mutation of the known Casein kinase II phophorylation site at amino acid residue 392 to either alanine or aspartic acid had no in¯uence on the half-life of p53 and on p53 stability regulation (see Table 2 , D62 ± 96 392A and D62 ± 96 392D). Additionally, the known cdk2 site at amino acid residue 315 was mutated to aspartic acid (D315) or the region was deleted (D309 ± 317 and D293 ± 322) in the D62 ± 96 form. Determination of the half-life revealed that these particular mutants were as unstable as wt p53 and that their stability was upregulated by UV light (Figure 7a and Table 2 ).
Since deletion of the N-terminal 43 amino acids resulted in a stable p53 form, it seemed possible that the phosphorylation status of this region is a critical determinant for p53 degradation. Therefore, all serines located in this region were mutated to either alanine (Nala) or aspartic acid (Nasp) in the context of the D62 ± 96 mutant. However, cell lines (RKO, U2OS, and H1299) stably expressing these particular mutants could be established only for the Nala mutant, suggesting that the presence of the negatively charged aspartic acid residues in this region of D62 ± 96 may restore its growth suppressive properties. Similar to the C-terminal phosphorylation mutants, Nala was degraded at a rate similar to wt p53 and its stability was upregulated upon UV-irradiation (Figure 7b ). In conclusion, these data strongly indicate that the phosphorylation status of the N-terminal as well as the C-terminal region of p53, at least with respect to the known phosphorylation sites, is not an essential determinant for the turnover rate of p53.
Discussion
The growth suppressive properties of p53 can be activated in response to a variety of stimuli, including DNA damage, hypoxia, ribonucletoide depletion and Table 2 Turnover of p53 mutant proteins in RKO cells before and upon UV-irradiation
L, long-lived protein with a half-life of 8 h or more; S, short-lived protein with a half-life similar to wt p53 (approximately 1 ± 2 h); n.a., not assessed; n.d., not determined Figure 6 Degradation and stabilization of N-terminal and Cterminal truncation mutants of p53. RKO cells stably expressing the indicated N-terminal and C-terminal deletion mutants of the D62 ± 96 form of wt p53 were established. Upon addition of cycloheximide, levels of endogenous wt p53 and the various mutants were determined at the indicated time periods by immunoblotting. In addition, levels of the DC30 mutant were determined upon UV treatment (UV). The p53 speci®c monoclonal antibodies used for immunoblotting were PAb1801 (DN20, DN43) and DO-1 (DC30, DC66). Running positions of endogenous wt p53 and of the deletion mutants are indicated by an asterisk or an arrowhead, respectively B Figure 7 None of the known p53 phosphorylation sites are necessary for p53 stability regulation. Phosporylation mutants of the D62 ± 96 form of wt p53 were generated and stably expressed in RKO cells. The half-life of the respective mutants was determined in cycloheximide experiments (Materials and methods) under normal growth conditions or upon UV-irradiation (UV). p53 was detected by immunoblotting using the monoclonal antibodies DO-1 (D315) or PAb 1801 (Nala). Running positions of endogenous wt p53 and the phosphorylation mutants are marked with an asterisk or an arrowhead, respectively. D315, substitution of serine at position 315 by aspartic acid; Nala, substitution of serine residues at position 6, 9, 15, 20, 33, and 37 by alanine the expression of activated oncogenes (Kastan et al., 1992; Lowe and Ruely, 1993; Graeber et al., 1996; Linke et al., 1996; Serrano et al., 1997) . As a result of p53 activation, treated cells are either growth arrested at distinct stages of the cell cycle or go into apoptosis. Despite the notion that upregulation of p53 stability seems to play an important role in p53 activation, the molecular mechanisms involved in p53 stability regulation are poorly understood. In the present study, an internal deletion mutant of human wt p53, termed D62 ± 96, was used to characterize amino acid regions of p53 that are required for p53 degradation and stability regulation. Since the protein stability of D62 ± 96 appears to be regulated similarly to wt p53, while being severely impaired with respect to the growth suppressive properties of wt p53, this mutant should prove useful to further delineate factors that are directly involved in p53 degradation and the mechanism(s) that lead to the upregulation of p53 stability upon treatment of cells with appropriate stimuli.
The notion that D62 ± 96 has a defect in growth suppression is supported by a study investigating the growth suppressive properties of a similar mutant, termed DproAE, containing a deletion of amino acids 62 ± 91 (Walker and Levine, 1996) . DproAE has a 5 ± 6-fold reduced eciency of growth suppression in cell culture as compared with wt p53. In contrast to D62 ± 96, it was reported that DproAE is an unstable protein in H1299 cells and that its stability can be upregulated by DNA damage. However, this notion was based on determination of steady state levels rather than on halflife measurements. Similar to D62 ± 96, expression of DproAE was under the control of the CMV promoter. Based on the results shown here for the DN43 mutant (see Figure 2) , a reasonable explanation for the apparent contradictory results is that the observed increase in DproAE protein level upon DNA damage was due to an increased expression or translation of the p53 message rather than to increased protein stability. This hypothesis is supported by the ®nding that CMV-based expression of other proteins with a long half-life, such as b-galactosidase, can be induced by UV light (AH and MS, unpublished data) .
Previous studies have suggested that the turnover rate of mutant p53 is at least in part dependent on the cellular context indicated by the fact that tumor mutants have a signi®cantly shortened half-life in wt p53 containing cells than in cells devoid of wt p53 (Halevy et al., 1989; Midgley and Lane, 1997 ). This hypothesis is strongly supported by the present study (Figure 4) . Moreover, the results obtained with the D62 ± 96 form of wt p53, which most probably adopts a wt-like conformation with respect to interaction with the HPV E6 oncoprotein (see Table 1 ), strongly indicate that p53-negative tumor cells or tumor cells harboring mutant p53 have lost the capacity to degrade wt p53. However, p53 forms oligomeric complexes and there is evidence to suggest that upon heterooligomerization, wt p53 aects the conformation of mutant p53 molecules, and vice versa (Milner and Medcalf, 1991; Milner, 1994) . Since oligomerization of p53 appears to be a prerequisite for degradation, an alternative explanation for the apparent cell typedependent degradation of mutant p53 is that mutant p53 molecules in complex with wt p53 adopt a protein conformation that is suitable for degradation. Similarly, one could envision that despite a wt-like conformation, D62 ± 96 is an intrinsically stable protein but is targeted by wt p53 via complex formation for degradation. This seems unlikely, however, since N-terminal deletion mutants of D62 ± 96 have a long half-life even in the presence of wt p53 (see Figure 6a) . Moreover, such N-terminal truncation mutants appear to negatively aect the turnover rate of wt p53. This indicates that the N-terminal region of p53 not only provides an essential determinant for p53 degradation but that this region has to be presented by several p53 molecules in an oligomeric complex to ensure ecient degradation.
Initial interest into characterizing the sequence and structural requirements for p53 degradation was raised to further de®ne the mechanism by which the HPV E6 oncoprotein can circumvent the normal p53 stability regulation. The data presented here show that, in contrast to p53 degradation in the absence of E6 within a cell, the N-terminal 20 ± 43 amino acids of p53 and the capacity to oligomerize are not required for E6-facilitated degradation of p53. Surprisingly, however, tumor mutants (135Y, 154A) which are not recognized by E6 due to an altered protein conformation (Schener et al., 1992) , are eciently degraded in non-HPV containing cells. Thus, the structural requirements for E6-independent p53 degradation appear to be less stringent. E6-induced ubiquitination and degradation of p53 is mediated by the cellular ubiquitin-protein ligase E6-AP. Interestingly, under certain conditions E6-AP can target p53 for ubiquitination in vitro in the absence of E6. However, the sequence requirements for E6-AP-induced ubiquitination of p53 in vitro are dierent to the requirements for p53 degradation within a cell with respect to the fact that the N-terminal 20 amino acids of p53 play a critical role only in the latter process. Taken together, these results indicate that the HPV E6 oncoprotein targets p53 for degradation by utilizing a component of the ubiquitin-conjugation system, i.e. E6-AP, that, based on the dierent sequence requirements, does not appear to play a major role in p53 degradation in normal non-HPV containing cells. This view is supported by recent studies from other laboratories (Beer-Romero et al., 1997; Talis et al., 1998) .
The observation that the N-terminal 43 amino acids are essential for p53 degradation in non-HPV containing cells raises the possibility that this region also plays a critical role in p53 stability regulation. The Nterminus of p53 contains several potential phosphorylation sites and some of these have been shown to be phosphorylated in response to DNA damage (Meek et al., 1997; Siliciano et al., 1997) . However, substitution of all the serines located in this region by alanine resulted in a short-lived protein that is stabilized upon treatment with UV light. Similarly, mutation or deletion of the known phosphorylation sites in the C terminus of p53 did not signi®cantly aect p53 degradation and stabilization. Thus, none of the known phosphorylation sites appear to be necessary for p53 stability regulation. However, it cannot be excluded that phosphorylation of certain residues may be sucient to induce stabilization of p53 as suggested previously (Fiscella et al., 1993; Shieh et al., 1997) , since, for instance, the half-life of a mutant in which all the serine residues in the N-terminus of p53 were substituted by aspartic acid could not be assessed (see Results). Regardless of whether the phosphorylation status of p53 aects its turnover rate, however, the data provided in the present study strongly indicate that the activity of a component of the p53 degradation system is regulated upon DNA damage. An obvious candidate is Mdm2 since, (i) the binding site for Mdm2 is located within the N-terminal 43 amino acids of p53 (Chen et al., 1993; Oliner et al., 1993) ; (ii) Mdm2 appears to be a major player in p53 degradation (Haupt et al., 1997; Kubbutat et al., 1997; Bottger et al., 1997) , and (iii) recently evidence was provided that Mdm2 is phosphorylated upon DNA damage and that this modi®cation may interfere with p53 binding (Mayo et al., 1997) . Alternatively, the activity of regulators of Mdm2 activity, such as p19ARF (Pomerantz et al., 1998; Zhang et al., 1998) , or of components of the ubiquitin-conjugation system that are intrinsically involved in p53 degradation, may be aected upon DNA damage.
Mdm2 gene expression is in part regulated by p53 (Momand and Zambetti, 1997; Piette et al., 1997) . Since the ability to eciently degrade p53 appears to correlate with the p53 status of a given cell, this suggests that cells lacking transcriptionally active p53 cannot target p53 for degradation because of reduced amounts of Mdm2 protein. Indeed, Western blot analysis, using an Mdm2-speci®c antibody, showed that p53-negative cells express considerably lower levels of Mdm2 than wt p53-positive cells. In addition, at present it cannot be excluded that a factor other than Mdm2 is absent in these cells and which is essential for p53 degradation or, alternatively, that the residual amount of Mdm2 present in p53-negative cells, or any other protein involved in p53 degradation, may be modi®ed in such a way that they cannot interact with p53. To test these possibilities it seems necessary to establish an in vitro degradation system for p53 which faithfully re¯ects the situation in vivo.
Materials and methods
Plasmids and protein expression
The p53 deletion mutants and point mutants were constructed by PCR ampli®cation using wt human p53 cDNA or tumor derived mutant p53 cDNAs (135Y, 154V, 179Q, 273H) as templates (Unger et al., 1992; Schener et al., 1992) . cDNAs encoding mutant p53s in which the serine residues at position 6, 9, 15, 20, 33, and 37 were substituted with alanine (Nala) and aspartic acid (Nasp), respectively, were kindly provided by T Unger. The cDNA encoding an oligomerization negative mutant of p53 (341K, 344E, 348E, 355K, or brie¯y KEEK) (StuÈ rzbecher et al., 1992) was kindly provided by JR Jenkins. All cDNAs were cloned by 5' HindIII and 3' XbaI digestion into the expression vector pRC/CMV (Invitrogen). DN20, DN43, and DN96 encode truncated forms of p53 with deletion of the N-terminal 20, 43, or 96 amino acids, respectively, while DC30 and DC66 encode truncated forms with deletions of the C-terminal 30 or 66 amino acids, respectively. To generate D44 ± 61, cDNAs encoding amino acids 1 ± 43 and 62 ± 393 were independently ampli®ed by PCR. The reverse primer for amino acids 1 ± 43 and the forward primer for amino acids 62 ± 393 contained an XhoI site at their respective 5'end which encodes the p53 amino acids 43 and 62. The two PCR products were ligated together at the XhoI site and cloned into pRC/CMV. D62 ± 96, D309 ± 317, D293 ± 322, and D315 (substitution of serine at position 315 with aspartic acid) were similarly cloned by independently amplifying cDNAs encoding the respective amino acids. The two cDNAs encoding D62 ± 96 were connected by an AatII site (encoding amino acids 61 and 97), the two cDNAs encoding D309 ± 317 and D315, respectively, were connected by blunt end ligation, and the two cDNAs encoding D293 ± 322 were connected by an HindIII site (encoding amino acids 292 and 323). All PCR generated cDNAs were sequenced to rule out that second site missense mutations were introduced during PCR ampli®cation.
For in vitro expression, the various forms of p53 and HPV-16 E6 were generated by in vitro transcriptiontranslation. The plasmid used encoding HPV-16 E6 is as described (Werness et al., 1990) . Transcription and translation was performed according to the manufacturer's instructions (Promega). Translation was performed in rabbit reticulocyte lysate in the presence of L-( 35 S)-methionine. E6-AP was expressed and prepared from Sf9 cells infected with a recombinant baculovirus encoding E6-AP as described . The ubiquitin-activating enzyme E1 and the ubiquitin-conjugating enzyme UbcH7 were expressed in E. coli BL21 using the pET expression system as described previously (Nuber et al., 1996) .
Cell lines, transfection and selection procedures H358, RKO, and U2OS cells were grown in RPMI media supplemented with 10% fetal calf serum. H1299, Saos-2, and C33-A cells were grown in DMEM supplemented with 10% fetal calf serum and NIH3T3 cells in DMEM supplemented with 10% newborn calf serum.
To generate cell lines stably expressing the various mutant forms of p53, cells were transfected with the respective expression constructs by lipofection (DOTAP) according to the manufacturer's instructions (Boehringer Mannheim). Cells stably containing the respective constructs were selected by resistance to neomycin (G418, Life Technologies). The neomycin resistance gene is encoded within the vector used for p53 expression (pRC/CMV). For half-life measurements, pooled clones, rather than single cell clones, were used as soon as practical after selection to ensure that the results obtained were not due to fortuitous integration of the expression vector at sites in the cellular genome that may aect the ability of a cell to degrade p53.
Half-life measurements and in vitro ubiquitination assays
For half-life measurements of the various p53 mutants, the respective cells were grown to con¯uency and then split 1 : 3 onto 6 cm plates. After 16 h, 60 mg/ml cycloheximide were added and the cells incubated for the indicated time periods. For pulse-chase analysis, cells were metabolically labeled with an L-( 35 S)-methionine/cysteine mix (Amersham) for 30 min (pulse), washed and then incubated in the presence of a 1000-fold excess of unlabeled methionine/ cysteine for the indicated time periods (chase). For UVirradiation, cells were treated with 50 J/m 2 in a UV Stratalinker (Stratagene) 5 min prior to the addition of cycloheximide. Protein extracts were prepared in 1% Nonidet P-40, 10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM DTT, 1 mM EDTA, 0.01% phenylmethylsulfonyl uoride, and 1 mg/ml aprotinin and leupeptin. For pulsechase experiments, the amount of radiolabeled p53 present in the extracts was determined by immunoprecipitation using mouse anti-p53 monoclonal antibodies. For immunoprecipitation, extracts containing equal amounts of trichloroacetic acid-precipitable radioactivity were used.
For determination of steady state levels of p53 (Figure 2 ), RKO cells at 60 ± 70% con¯uency were treated with UVSequence elements involved in p53 degradationirradiation (50 J/m 2 ) or not, as indicated. After 16 h, whole cell extracts were prepared as described above.
For Western blotting, equal amounts of protein were separated on 10% SDS-polyacrylamide gels and blotted onto PVDF membranes (Millipore). Mouse monoclonal antibody PAb 1801 (Dianova) was used to detect N-terminal truncation and phosphorylation (Nala, Nasp) mutants of p53 followed by ECL according to the manufacturer's instructions (Amersham). For all other p53 mutants, mouse monoclonal antibody DO-1 (Dianova) was used. For Mdm2, equal amounts of protein were immunoprecipitated using a rabbit polyclonal anti-Mdm2 antibody. After SDS-polyacrylamide gel electrophoresis and blotting onto PVDF membranes, the mouse monoclonal antibody Mdm2 (Ab-1) (Dianova) was used to detect Mdm2 followed by ECL. Relative amounts of Mdm2 were determined by densitometry.
p53 ubiquitination assays in the presence of the HPV E6 oncoprotein were performed as described previously (Schener et al., 1992) . For p53 ubiquitination assays in the absence of E6, 2 ml of rabbit reticulocyte lysate translated p53 were incubated in the presence of the indicated amounts of puri®ed baculovirus expressed E6-AP, 50 ng E1, 50 ng UbcH7, and 6 mg ubiquitin (SIGMA) in 100 ml volumes. In addition, reactions contained 20 mM Tris-HCl (pH 7.6), 20 mM NaCl, 4 mM DTT, 2 mM ATP-g-S (Boehringer Mannheim), and 4 mM MgCl 2 . After incubation at 258C for 2 h, total reaction mixtures were electrophoresed on 10% SDS-polyacrylamide gels and 35 S-labeled p53 detected bȳ uorography.
